The US Food and Drug Administration (FDA) granted accelerated approval on 5 November 2026 to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for adults with recurrent or metastatic head and neck squamous cell carcinoma whose disease has progressed on or after platinum-based chemotherapy and immunotherapy. It is the first approval in ten years for patients in this setting, where treatment options have been limited and outcomes poor.
What the Trial Showed
Approval was based on cohort 1 of the phase 1b/2 OrigAMI-4 trial, an open-label, multicentre study of 102 adults with recurrent or metastatic head and neck squamous cell carcinoma who had already received platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor. The overall response rate was 42%, meaning tumours shrank or disappeared in just over two in five patients, including complete responses in 15% of patients. Among those who responded, 56% had a response lasting six months or longer.
The FDA noted that currently approved therapies for this group are associated with a response rate of around 20% or less and poor outcomes, and said the trial results showed more than double the percentage of patients responding compared with those therapies. The results were published in the Journal of Clinical Oncology. Angelo De Claro, director of the FDA's Oncology Center of Excellence, said the approval was a meaningful step forward for patients with a disease where treatment options have historically been limited.
Who the Approval Covers
The approval covers adults with recurrent or metastatic head and neck squamous cell carcinoma that has progressed on or after platinum-based chemotherapy and an immune checkpoint inhibitor. It does not cover patients with oropharyngeal squamous cell carcinoma associated with human papillomavirus (HPV). Rybrevant Faspro is given as a single agent by injection under the skin, and it targets two proteins, EGFR and MET, that can help cancer cells grow.
This is the first approval for Rybrevant Faspro outside lung cancer, where it was previously approved for certain patients with EGFR-mutated non-small cell lung cancer. The FDA granted the drug Breakthrough Therapy designation for this indication in February 2026 and priority review in July 2026. The approval was granted to Janssen Biotech, part of Johnson & Johnson.
What Accelerated Approval Means
Accelerated approval allows a drug for a serious condition with high unmet need to reach patients earlier, based on a surrogate or intermediate endpoint, in this case overall response rate and duration of response. Because it is not yet confirmed whether the responses will translate into a clinically meaningful benefit in long-term outcomes, the FDA has required confirmatory studies to verify and describe the clinical benefit, and continued approval may depend on those results.
The designated confirmatory study is the phase 3 OrigAMI-5 trial, which is testing Rybrevant Faspro with the chemotherapy carboplatin and the immunotherapy pembrolizumab as a first treatment for recurrent or metastatic head and neck cancer. The prescribing information includes warnings and precautions for hypersensitivity and administration-related reactions, interstitial lung disease or pneumonitis, dermatologic adverse reactions, ocular toxicity and harm to an unborn baby.
Why This Matters for Healthcare Organizations
For clinics and hospitals, the practical effect is in referral and follow-up. Patients with recurrent or metastatic head and neck cancer who have already had chemotherapy and immunotherapy have had very few options, and many practices will now see questions from patients and families about whether this treatment applies to them. Front-desk and care teams should know the eligibility limits, including the HPV-associated oropharyngeal exclusion, so referrals go to the right oncology service without delay.
The subcutaneous administration is also worth noting for infusion services. Unlike intravenous cancer therapies, Rybrevant Faspro is injected under the skin, which changes how a dose is given and monitored. Practices that coordinate oncology referrals should confirm with their oncology partners how the treatment is delivered and what follow-up, including monitoring for skin, eye and lung reactions, is expected after each dose.
Analysis: A Strong Response Rate, With the Usual Accelerated Approval Caveats
The 42% response rate is the headline, and it is strong against the roughly 20% seen with existing options. But the evidence comes from a single-arm, open-label cohort of 102 patients, so the response rate cannot be compared directly with other treatments, and no survival outcomes were reported. The FDA's own comparison to currently approved therapies is against historical figures, not a head-to-head trial.
The confirmatory picture is also unusual. OrigAMI-5 tests Rybrevant Faspro as part of a first-line combination, a different setting and regimen from the approved second-line single-agent use. Even a positive result there will not directly confirm the benefit of the treatment as approved. That is a known feature of accelerated approvals, not a flaw in this one, but it means the evidence base for the approved use will stay thin until longer follow-up from OrigAMI-4 itself is published.
Clinics reviewing how front-desk and patient communication work can be handled can explore MedClinicX's AI patient portal, see how after-hours calls are handled on our AI medical receptionist page, or explore the demos and request a quote. For related coverage, see our earlier articles on FDA granting accelerated approval to Voceryq, the first plasmid DNA immunotherapy for a rare airway disease and FDA approving Ilumya for adults with active psoriatic arthritis.
Sources and References
- U.S. Food and Drug Administration — FDA Grants Accelerated Approval to a New Treatment for Head and Neck Squamous Cell Carcinoma, 5 November 2026: https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-new-treatment-head-and-neck-squamous-cell-carcinoma
- Johnson & Johnson — Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer, 5 November 2026: https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-u-s-fda-approval-of-rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-as-first-and-only-dual-targeted-therapy-for-advanced-head-and-neck-cancer
- Pharmaceutical Executive — FDA Grants Accelerated Approval to Rybrevant Faspro in Head and Neck Cancer, 6 November 2026: https://www.pharmexec.com/view/fda-accelerated-approval-rybrevant-faspro-head-neck-cancer
- CURE Today — FDA Approves Rybrevant Faspro for Advanced Head and Neck Cancer, 6 November 2026: https://www.curetoday.com/view/fda-approves-rybrevant-faspro-for-advanced-head-and-neck-cancer
Reporting based on the sources above, accessed 7 November 2026. The FDA press release was read directly, and the Johnson & Johnson, Pharmaceutical Executive and CURE Today reports were read directly and cross-checked against it. MedClinicX did not conduct original reporting or interviews for this article. Corrections: contact us via https://medclinicx.com/contact